info@armstrongclinical.com

Category: Clinical Development

Biotech Commercialisation. Why an Accurate Clinical Development Forecast is Necessary Early in Drug Development

The aim for many biotech companies taking a discovery into clinical development will be to generate data from phase 1 studies, not only to understand the potential of their discovery but often also to attract further investment or a potential licensing deal.  However, one of the keys for the successful commercialization of any therapy is…
Read more

Continuing Non-Clinical Evidence Generation Throughout Drug Development:

Important goals of pre-clinical drug development programs (in silico, in vivo, in vitro studies) include the formulation of precise estimates correlating preclinical results to clinical outcomes and to make sure sufficient data has been generated for a new therapy to enter first in human clinical studies. Information generated pre-clinically will also frame the first in…
Read more

Clinical Trials in Australia: Some Key Points

The Australian clinical trial industry is large and growing fast. Roughly 1,360 new clinical trials were conducted in Australia in 2015, and since 2010, this number has grown at approximately 5 percent per year. In this post we will point out some key points about conducting Clinical Trials in Australia.

Why Conduct Clinical Trials in Australia?

Australia has a rapidly growing clinical trial sector thanks to the number of advantages that it offers as a clinical trial destination. Robust Regulatory Framework, government incentives, high quality standards, and availability of skilled workforce are a few of them. Here we summarize a few reasons about why you should conduct clinical trials in Australia.


I accept the Privacy Policy